For how we live.
Satralizumab, cleared on 15 October, is the first interleukin-6 receptor blocker approved for the eye-bulging autoimmune disease. One of its two identical trials hit the main goal; the other missed it.
In the phase 3 THRIVE trial, veligrotug shrank bulging eyes in 70% of patients versus 5% on placebo. It is the first serious challenger to the only drug approved for the condition.
Satralizumab reduced eye-bulging and inflammation in thyroid eye disease across the twin SatraGO phase 3 trials, but the primary proptosis endpoint reached statistical significance in only one of them.